NIAGEN BIOSCIENCE INC (NAGE) Stock News

NASDAQ:NAGE - Nasdaq - US1710774076 - Common Stock - Currency: USD

10.26 +0.44 (+4.48%)

After market: 10.3 +0.04 (+0.39%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NAGE Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill - Mentions: EXAS TPC CREG TNDM ...

News Image

Stay updated with the stocks that are on the move in today's after-hours session.

2 days ago - By: Benzinga

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

6 days ago - By: Benzinga - Mentions: EXAS TNDM IRWD OM ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

6 days ago - By: Zacks Investment Research - Mentions: CRVO

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

6 days ago - By: The Motley Fool

Niagen NAGE Q2 2025 Earnings Call Transcript

6 days ago - By: Niagen Bioscience, Inc.

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

9 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

21 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

a month ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

a month ago - By: Niagen Bioscience, Inc

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate in the BIO 2025 International Convention

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

3 months ago - By: Zacks Investment Research - Mentions: NVAX

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates

3 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

3 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

5 months ago - By: Niagen Bioscience, Inc

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science